Ceftriaxone Protects Astrocytes from MPP+ via Suppression of NF-κB/JNK/c-Jun Signaling
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Ceftriaxone has been shown to attenuate the dopaminergic neuron death and alleviate behavioral disorders in Parkinson's disease models via upregulation of glutamate transporter-1 (GLT-1) and decreases in extracellular glutamate. However, details of how this neuroprotection occurs are uncertain. We hypothesized that cytoprotection by ceftriaxone in astrocytes exposed to 1-methyl-4-phenylpyridinium (MPP(+)) involves suppression of the NF-κB/JNK/c-Jun signaling pathway. Here, we observed a protective effect of ceftriaxone in primary astrocytes exposed to MPP(+). Ceftriaxone enhanced glutamate uptake and promoted primary astrocyte viability after MPP(+) exposure. Ceftriaxone enhances glutamate uptake via upregulation of GLT-1 in the plasma membrane, and alleviates MPP(+)-induced neurotoxicity via suppression of NF-κB/JNK/c-Jun signaling. Collectively, our data offer evidence that increased expression and function of GLT-1 are involved in the protective mechanism of ceftriaxone in astrocytes exposed to MPP(+) in vitro, and we offer insight into the potential therapeutic role of ceftriaxone in treatment of Parkinson's disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mechanistically, CTX also reduces extracellular glutamate levels by increasing the expression of the glutamate transporter-1 in astrocytes, thus avoiding brain excitotoxicity [226,228,229].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [228]
In the citing paper
“The treatment of several PD animal models with CTX is known to improve neuroinflammatory and oxidative stress markers, stimulate neurogenesis and promote astrocyte viability through the suppression of NF-κB/c-Jun-mediated signaling [225,226,227,228].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [228]
In the citing paper
“The treatment of several PD animal models with CTX is known to improve neuroinflammatory and oxidative stress markers, stimulate neurogenesis and promote astrocyte viability through the suppression of NF-κB/c-Jun-mediated signaling [225,226,227,228].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [228]
In the citing paper
“The treatment of several PD animal models with CTX is known to improve neuroinflammatory and oxidative stress markers, stimulate neurogenesis and promote astrocyte viability through the suppression of NF-κB/c-Jun-mediated signaling [225,226,227,228].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [228]
In the citing paper
“Mechanistically, CTX also reduces extracellular glutamate levels by increasing the expression of the glutamate transporter-1 in astrocytes, thus avoiding brain excitotoxicity [226,228,229].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [228]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
1 retracted
Disturbed Neurotransmitter Transporter Expression in Alzheimer’s Disease Brain
Chen, K. H., Reese, E. A., Kim, H.-W., Rapoport, S. I., & Rao, J. S. (2011) · Journal of Alzheimer’s Disease · doi:10.3233/jad-2011-110002 · Cited by 122
RetractedThe relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481 · cited 1×
“PD is characterized by selective loss of dopaminergic neurons and the formation of Lewy bodies in the substantia nigra pars compacta (SNc) [4, 5].”
Rothstein, J. D., Dykes-Hoberg, M., Pardo, C. A., Bristol, L. A., Jin, L., Kuncl, R. W., Kanai, Y., Hediger, M. A., Wang, Y., Schielke, J. P., et al. (1996) · Neuron · doi:10.1016/s0896-6273(00)80086-0 · Cited by 2,534
Ankarcrona, M., Dypbukt, J. M., Bonfoco, E., Zhivotovsky, B., Orrenius, S., Lipton, S. A., & Nicotera, P. (1995) · Neuron · doi:10.1016/0896-6273(95)90186-8 · Cited by 1,884
Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000) · Science · doi:10.1126/science.287.5456.1265 · Cited by 1,765 · cited 1×
“PD is characterized by selective loss of dopaminergic neurons and the formation of Lewy bodies in the substantia nigra pars compacta (SNc) [4, 5].”
β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression
Rothstein, J. D., Patel, S., Regan, M. R., Haenggeli, C., Huang, Y. H., Bergles, D. E., Jin, L., Dykes Hoberg, M., Vidensky, S., Chung, D. S., et al. (2005) · Nature · doi:10.1038/nature03180 · Cited by 1,518 · cited 6×
“Because the increased GLT-1 expression could be seen as early as 48 h after ceftriaxone treatment [18], so we chose to treat with ceftriaxone for 48 h.”
InfluentialRapid proteolysis of IκB-α is necessary for activation of transcription factor NF-κB
Henkel, T., Machleidt, T., Alkalay, I., Krönke, M., Ben-Neriah, Y., & Baeuerle, P. A. (1993) · Nature · doi:10.1038/365182a0 · Cited by 1,104
Excitotoxicity: Bridge to various triggers in neurodegenerative disorders
Mehta, A., Prabhakar, M., Kumar, P., Deshmukh, R., & Sharma, P. L. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.10.032 · Cited by 665
Glutamate Transporter Protein Subtypes Are Expressed Differentially during Rat CNS Development
Furuta, A., Rothstein, J. D., & Martin, L. J. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-21-08363.1997 · Cited by 552 · cited 1×
“GLT-1 is highly expressed in astrocytes and accounts for most of the glutamate uptake in the synaptic cleft [15].”
Levodopa motor complications in Parkinson's disease
Obeso, J. A., Olanow, C. W., & Nutt, J. G. (2000) · Trends in Neurosciences · doi:10.1016/s1471-1931(00)00031-8 · Cited by 478 · cited 1×
“However, prolonged treatment with L-DOPA leads to side effects such as diminished efficacy, dyskinesia, and mental symptoms such as delirium [6].”
Cited by
The Role of Astrocyte Dysfunction in Parkinson’s Disease Pathogenesis
Booth, H. D. E., Hirst, W. D., & Wade-Martins, R. (2017) · Trends in Neurosciences · doi:10.1016/j.tins.2017.04.001 · Cited by 633
Glutamate-induced excitotoxicity in Parkinson's disease: The role of glial cells
Iovino, L., Tremblay, M. E., & Civiero, L. (2020) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2020.07.011 · Cited by 374
Miao, Z., Miao, Z., Wang, S., Wu, H., & Xu, S. (2022) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2021.12.017 · Cited by 160
Cadmium induces BNIP3-dependent autophagy in chicken spleen by modulating miR-33-AMPK axis
Chen, M., Li, X., Fan, R., Yang, J., Jin, X., Hamid, S., & Xu, S. (2017) · Chemosphere · doi:10.1016/j.chemosphere.2017.12.026 · Cited by 111
Regulation of glutamate transporter trafficking by Nedd4-2 in a Parkinson’s disease model
Zhang, Y., He, X., Meng, X., Wu, X., Tong, H., Zhang, X., & Qu, S. (2017) · Cell Death and Disease · doi:10.1038/cddis.2016.454 · Cited by 99
Metadata
- Authors
- Zhang, Y., Zhang, X., & Qu, S.
- Affiliations
- Southern Medical University (CN)
- Corresponding author
- Qu, Shaogang
- Venue
- Molecular Neurobiology
- Published
- 2014-08-12
- Volume
- 52
- Issue
- 1
- Pages
- 78-92
- ISSN
- 0893-7648 (ISSN-L)
- 1559-1182
- OpenAlex
- W2085369506
- Cited by
- 39
- References
- 47
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 3 · 2023: 3 · 2022: 2 · 2021: 8 · 2020: 5 · 2019: 2 · 2018: 1 · 2017: 10 · 2016: 1
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Molecular Neurobiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Science and Technology Planning Project of Guangdong Province
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- ceftriaxone, astrocytes, MPP+, Parkinson's disease, neuroprotection, NF-κB signaling, JNK signaling, c-Jun, GLT-1, glutamate uptake, neurotoxicity, dopaminergic neurons
- MeSH terms
- Neuroprotection, Animals, Aspartic Acid, Astrocytes, Ceftriaxone, Cell Survival, Cells, Cultured, Kinetics, 1-Methyl-4-phenylpyridinium, Up-Regulation, NF-kappa B, Proto-Oncogene Proteins c-jun, Cell Death, Rats, Sprague-Dawley, Neuroprotective Agents, Glutamic Acid, MAP Kinase Signaling System
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ceftriaxone Protects Astrocytes from MPP+ via Suppression of NF-κB/JNK/c-Jun Signaling. https://app.cochat.ai/papers/10.1007/s12035-014-8845-z
- The paper
- Zhang, Y., Zhang, X., & Qu, S. (2015). Ceftriaxone Protects Astrocytes from MPP+ via Suppression of NF-κB/JNK/c-Jun Signaling. Molecular Neurobiology. https://doi.org/10.1007/s12035-014-8845-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.